[[dashboard:report_kpm_von_2013-2024]]
Mostra pagina
Ultime modificheIndice

Differenze

Queste sono le differenze tra la revisione selezionata e la versione attuale della pagina.

Link a questa pagina di confronto

Entrambe le parti precedenti la revisioneRevisione precedente
Prossima revisione		Revisione precedente
dashboard:report_kpm_von_2013-2024 [2025/07/02 21:19] – [📈 Pneumothorax - Sporadic Critical Events] admindashboard:report_kpm_von_2013-2024 [2025/07/04 21:50] (versione attuale) – [📈 12-Year Journey Summary] admin
Linea 10: Linea 10:
 | **🔴 CONCERN** | 2/10 | **Significant deviation** | ⚠️ **ATTENTION** | | **🔴 CONCERN** | 2/10 | **Significant deviation** | ⚠️ **ATTENTION** |
  
---- 
- 
-/* 1. MORTALITY CONTROL CHART (2013-2024)\* 
  
 ===== 📈 Mortality Trend - 12 Year Analysis ===== ===== 📈 Mortality Trend - 12 Year Analysis =====
Linea 87: Linea 84:
 - **2024:** 2.9% - **Miglior performance bilanciata** della serie storica - **2024:** 2.9% - **Miglior performance bilanciata** della serie storica
 - **Capability:** Processo sotto controllo statistico, trend migliorativo - **Capability:** Processo sotto controllo statistico, trend migliorativo
 +
 +
 +
 +
 +
 +===== 📈 Death or Morbidity - Stabilità Controllata =====
 +
 +<achart>
 +{
 +  "chart": {
 +    "type": "line",
 +    "height": 450
 +  },
 +  "title": {
 +    "text": "Death or Morbidity Control Chart (2013-2024)"
 +  },
 +  "series": [
 +    {
 +      "name": "Death or Morbidity",
 +      "data": [31.9, 29.6, 45.8, 37.9, 24.0, 19.4, 26.9, 27.3, 30.8, 34.5, 41.4, 35.3]
 +    },
 +    {
 +      "name": "CL (32.1%)",
 +      "data": [32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1]
 +    },
 +    {
 +      "name": "UCL (46.3%)",
 +      "data": [46.3, 46.3, 46.3, 46.3, 46.3, 46.3, 46.3, 46.3, 46.3, 46.3, 46.3, 46.3]
 +    },
 +    {
 +      "name": "LCL (17.8%)",
 +      "data": [17.8, 17.8, 17.8, 17.8, 17.8, 17.8, 17.8, 17.8, 17.8, 17.8, 17.8, 17.8]
 +    }
 +  ],
 +  "xaxis": {
 +    "categories": [2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024]
 +  },
 +  "colors": ["#DC3545", "#28A745", "#FF0000", "#0066CC"],
 +  "stroke": {
 +    "width": [3, 2, 2, 2],
 +    "dashArray": [0, 5, 3, 3]
 +  }
 +}
 +</achart>
 +
 +
 +**Analisi Death or Morbidity:**
 +- **Media storica 12 anni:** 32.1%
 +- **2024:** 35.3% (sopra media ma sotto UCL)
 +- **Range:** 19.4% (2018) - 45.8% (2015)
 +- **Status:** Processo sotto controllo statistico
 +- **Trend:** Variabilità contenuta entro limiti accettabili
 +
 +**Key Events:**
 +- **2015:** Picco massimo 45.8%
 +- **2018:** Minimo storico 19.4%
 +- **2024:** Performance controllata, sopra media ma stabile
  
 --- ---
  
-/* 2. MAJOR MORBIDITY CONTROL CHARTS\*+/*2. ANY LATE INFECTION CONTROL CHART\*
  
-===== 📈 Death or Morbidity + Late Infection Trends =====+===== 📈 Any Late Infection - Storia di Successo =====
  
 <achart> <achart>
Linea 98: Linea 152:
   "chart": {   "chart": {
     "type": "line",     "type": "line",
-    "height": 500, +    "height": 450
-    "background": "#fafafa"+
   },   },
   "title": {   "title": {
-    "text": "Major Morbidity Control Charts (2013-2024)", +    "text": "Any Late Infection Control Chart (2013-2024)"
-    "align": "center"+
   },   },
   "series": [   "series": [
     {     {
-      "name": "💀 Death or Morbidity", +      "name": "Any Late Infection", 
-      "data": [31.9, 29.6, 45.8, 37.9, 24.0, 19.4, 26.9, 27.3, 30.8, 34.5, 41.4, 35.3], +      "data": [16.3, 22.2, 28.3, 31.0, 12.5, 13.9, 15.4, 18.8, 15.4, 19.4, 11.1, 5.9]
-      "color": "#DC3545"+
     },     },
     {     {
-      "name": "🦠 Any Late Infection", +      "name": "CL (17.5%)", 
-      "data": [16.3, 22.2, 28.3, 31.0, 12.5, 13.9, 15.4, 18.8, 15.4, 19.4, 11.1, 5.9], +      "data": [17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5]
-      "color": "#FF6B6B"+
     },     },
     {     {
-      "name": "🎯 CL Death/Morbidity (32.1%)", +      "name": "UCL (31.1%)", 
-      "data": [32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1, 32.1], +      "data": [31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1]
-      "color": "#28A745"+
     },     },
     {     {
-      "name": "🎯 CL Late Infection (17.5%)", +      "name": "LCL (4.0%)", 
-      "data": [17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5, 17.5], +      "data": [4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0]
-      "color": "#17A2B8"+
     },     },
     {     {
-      "name": "🔴 UCL Late Infection (31.1%)", +      "name": "Target VON 8%", 
-      "data": [31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1, 31.1], +      "data": [8.0, 8.0, 8.0, 8.0, 8.0, 8.0, 8.0, 8.0, 8.0, 8.0, 8.0, 8.0]
-      "color": "#FF0000"+
     }     }
   ],   ],
   "xaxis": {   "xaxis": {
-    "categories": [2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024], +    "categories": [2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024]
-    "title": { "text": "Anno" } +
-  }, +
-  "yaxis": { +
-    "title": { "text": "Percentuale (%)" }, +
-    "min": 0, +
-    "max": 50+
   },   },
 +  "colors": ["#FF6B6B", "#28A745", "#FF0000", "#0066CC", "#FFC107"],
   "stroke": {   "stroke": {
-    "width": [4, 3, 2, 2, 2], +    "width": [4, 2, 2, 2, 2], 
-    "dashArray": [0, 0, 5, 5, 3] +    "dashArray": [0, 5, 3, 3, 8]
-  }, +
-  "markers": { "size": [8, 6, 0, 0, 0] }, +
-  "annotations": { +
-    "points": [ +
-      { +
-        "x": 3, +
-        "y": 31.0, +
-        "marker": { "size": 10, "fillColor": "#FF0000" }, +
-        "label": { "text": "2016 PEAK", "style": { "color": "#fff", "background": "#FF0000" }} +
-      }, +
-      { +
-        "x": 11, +
-        "y": 5.9, +
-        "marker": { "size": 12, "fillColor": "#00AA00" }, +
-        "label": { "text": "2024 BEST", "style": { "color": "#fff", "background": "#00AA00" }} +
-      } +
-    ]+
   }   }
 } }
Linea 167: Linea 192:
 **🔍 Key Insights:** **🔍 Key Insights:**
 - **Late Infection:** Drammatico miglioramento da 31% (2016) a 5.9% (2024) - **Late Infection:** Drammatico miglioramento da 31% (2016) a 5.9% (2024)
-- **Death/Morbidity:** Stabile intorno alla media, con miglioramento 2024+
  
 --- ---
Linea 464: Linea 489:
 --- ---
  
-## 7. SEVERE ROP - OPHTHALMOLOGIC EXCELLENCE+/* 7. SEVERE ROP - OPHTHALMOLOGIC EXCELLENCE\*
  
 ===== 📈 Severe ROP Control Chart - Consistent Excellence ===== ===== 📈 Severe ROP Control Chart - Consistent Excellence =====
Linea 516: Linea 541:
 --- ---
  
-## 8. ANY HUMAN MILK - NUTRITION RECOVERY+/*8. ANY HUMAN MILK - NUTRITION RECOVERY\*
  
 ===== 📈 Any Human Milk - Complete Recovery Journey ===== ===== 📈 Any Human Milk - Complete Recovery Journey =====
Linea 610: Linea 635:
 --- ---
  
-## 9. COMPREHENSIVE STATISTICAL SUMMARY+/*9. COMPREHENSIVE STATISTICAL SUMMARY\*
  
 ===== 📊 12-Year Performance Statistics - All Metrics ===== ===== 📊 12-Year Performance Statistics - All Metrics =====
Linea 644: Linea 669:
 --- ---
  
-## 10. PROCESS CAPABILITY ANALYSIS+/*10. PROCESS CAPABILITY ANALYSIS\*
  
 ===== 🎯 12-Year Capability Assessment ===== ===== 🎯 12-Year Capability Assessment =====
Linea 678: Linea 703:
 --- ---
  
-## 11. STRATEGIC DASHBOARD & RECOMMENDATIONS+/* 11. STRATEGIC DASHBOARD & RECOMMENDATIONS\*
  
 ===== 🎯 Strategic Assessment Based on 12-Year Analysis ===== ===== 🎯 Strategic Assessment Based on 12-Year Analysis =====
Linea 765: Linea 790:
  
 **Next Chapter:** Focus surgical intervention on 2 remaining challenges (NEC + Pneumothorax) while maintaining the excellence achieved in 8 other key metrics. **Next Chapter:** Focus surgical intervention on 2 remaining challenges (NEC + Pneumothorax) while maintaining the excellence achieved in 8 other key metrics.
 +
 +
 +
 +<WRAP left round box 15%>
 +[[dashboard:report_attivita_e_monitoraggio_esiti|Torna a dashboard ]]
 +</WRAP>
 +
dashboard/report_kpm_von_2013-2024.1751483977.txt.gz · Ultima modifica: da admin
Mostra paginaRevisioni precedenti
Gestore MediaTorna su